VXL — Vaxil Bio Balance Sheet
0.000.00%
Last trade - 00:00- CA$0.90m
- CA$0.23m
Annual balance sheet for Vaxil Bio, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 2.24 | 1.51 | 0.938 | 0.448 | 0.671 |
| Net Total Receivables | 0.035 | 0.02 | 0.019 | 0.273 | 0.003 |
| Prepaid Expenses | |||||
| Total Current Assets | 2.28 | 1.54 | 0.976 | 0.733 | 0.685 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.002 | 0 | — | — | — |
| Long Term Investments | |||||
| Total Assets | 2.29 | 1.54 | 0.976 | 0.733 | 1.37 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 0.585 | 0.405 | 0.085 | 0.017 | 0.005 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.585 | 0.405 | 0.085 | 0.017 | 0.005 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1.7 | 1.14 | 0.891 | 0.716 | 1.36 |
| Total Liabilities & Shareholders' Equity | 2.29 | 1.54 | 0.976 | 0.733 | 1.37 |
| Total Common Shares Outstanding |